40
Participants
Start Date
April 21, 2020
Primary Completion Date
April 30, 2024
Study Completion Date
October 31, 2025
Adalimumab treatment
Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
RECRUITING
Service Neuropédiatrie, Marseille
NOT_YET_RECRUITING
Chu de Bordeaux, Bordeaux
NOT_YET_RECRUITING
Chu Brest, Brest
NOT_YET_RECRUITING
Chru de Lille, Lille
NOT_YET_RECRUITING
Chu Limoges, Limoges
NOT_YET_RECRUITING
Hospices Civils de Lyon, Lyon
NOT_YET_RECRUITING
Chu Montpellier, Montpellier
NOT_YET_RECRUITING
Chu de Nancy, Nancy
NOT_YET_RECRUITING
Chu Necker Ap-Hp, Paris
NOT_YET_RECRUITING
Chu Pitie Salpietriere Ap-Hp, Paris
NOT_YET_RECRUITING
Chu Robert Debre, Paris
NOT_YET_RECRUITING
Fondation Adolphe de Rothshild, Paris
NOT_YET_RECRUITING
Chu de Rennes, Rennes
NOT_YET_RECRUITING
Chu Strasbourg, Strasbourg
NOT_YET_RECRUITING
Chu Toulouse, Toulouse
NOT_YET_RECRUITING
Chru de Tours, Tours
Assistance Publique Hopitaux De Marseille
OTHER